Moderna announced the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases to claim the high efficacy.
undefined
The trial results come at a time when the coronavirus pandemic has infected over 63 million people and killed more than 1.4 million across the world. The data analysis indicates a vaccine efficacy of 94.1%. But when it came to severe COVID-19, mRNA-1273 vaccine's efficacy reached 100%
undefined
In a statement, Moderna said: "Efficacy was consistent across age, race and ethnicity, and gender demographics. The 196 COVID-19 cases included 33 older adults (ages 65+) and 42 participants identifying as being from diverse communities (including 29 Hispanic or LatinX, 6 Black or African Americans, 4 Asian Americans and 3 multiracial participants)."
undefined
Stéphane Bancel, Chief Executive Officer of Moderna, said: "This positive primary analysis confirms the ability of our vaccine to prevent COVID-19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID-19 disease. We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death."
undefined
Later tonight, Moderna will submit for an Emergency Use Authorisation with the U.S FDA and an application for Conditional Marketing Authorization with the European Medicines Agency. The Company anticipates that the shipping of mRNA-1273 to designated distribution points throughout the U.S. will occur shortly after an Emergency Use Authorization is granted.
undefined